Tekla Life Sciences Investors
HQL · NYSE
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $0 | $0 | $0 | $0 |
| Short-Term Investments | $12 | $0 | $0 | $15 |
| Receivables | $6 | $0 | $0 | $5 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | -$19 | $0 | $0 | -$15 |
| Total Curr. Assets | $0 | $0 | $0 | $5 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $460 | $430 | $398 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $14 | $12 | $0 |
| Total NC Assets | $0 | $474 | $442 | $398 |
| Other Assets | $411 | -$14 | $0 | $0 |
| Total Assets | $411 | $461 | $442 | $403 |
| Liabilities | – | – | – | – |
| Payables | $0 | $0 | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $0 | $1 | $1 | $0 |
| Total Curr. Liab. | $0 | $1 | $1 | $0 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $1 | $1 | $1 |
| Total NC Liab. | $0 | $1 | $1 | $1 |
| Other Liabilities | $15 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $15 | $1 | $1 | $1 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$31 | $44 | $30 | -$1 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $426 | $415 | $411 | $403 |
| Total Equity | $396 | $460 | $441 | $402 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $411 | $461 | $442 | $403 |
| Net Debt | $0 | $0 | $0 | -$0 |